Findings from three large platform trials suggest that therapeutic anticoagulation for thromboembolic prophylaxis was associated with improved outcomes and possibly survival in hospitalized but not critically ill COVID-19 population.

The full-dose treatment approach was found to be superior to prophylactic dosing for decreasing the proportion of patients progressing to ventilation requirement and other vital organ support across the three adaptive platform trials ACTIV-4a trial, REMAP-CAP, and ATTACC. Therapeutic dosing appeared to be safe in the moderately ill COVID-19 patients, contrary to the critically ill population, for which the trials had to stop the full-dose strategy after indications of harm. Complete results of the three trials will be released later… (Medpage Today)